

GREENWAY MEDICAL TECHNOLOGIES INC
 Form 4
 February 09, 2012

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL
 OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
INVESTOR AB

2. Issuer Name and Ticker or Trading Symbol
GREENWAY MEDICAL TECHNOLOGIES INC [GWAY]

5. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
 02/07/2012

___ Director ___X___ 10% Owner
 ___ Officer (give title below) ___ Other (specify below)

C/O INVESTOR GROWTH CAPITAL, ONE ROCKEFELLER PLAZA, SUITE 2801

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 ___X___ Form filed by One Reporting Person
 ___ Form filed by More than One Reporting Person

NEW YORK, NY 10020

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) | | |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|--|---|--|
| | | | Code | V | Amount | (A) or (D) | Price | | |
| Common Stock | 02/07/2012 | | C | | 2,735,526 | A (3) | 3,970,821 | I | By Investor Growth Capital Limited (1) (2) |
| Common Stock | 02/07/2012 | | C | | 951,188 | A (4) | 4,922,009 | I | By Investor Growth Capital |

| | | | | | | | | |
|--------------|------------|---|-----------|---|------------|-----------|---|--|
| Common Stock | 02/07/2012 | C | 1,172,368 | A | <u>(3)</u> | 1,701,779 | I | Limited <u>(1)</u> <u>(2)</u> By Investor Group, L.P. <u>(1)</u> <u>(2)</u> |
| Common Stock | 02/07/2012 | C | 407,652 | A | <u>(4)</u> | 2,109,431 | I | By Investor Group, L.P. <u>(1)</u> <u>(2)</u> |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|
| | | | | Code | V (A) (D) | Date Exercisable Expiration Date | Title Amount Number Shares |
| Series A Convertible Preferred Stock | <u>(3)</u> | 02/07/2012 | | C | 1,750,000 <u>(3)</u> | <u>(3)</u> <u>(3)</u> | Common Stock 2,210, |
| Series A Convertible Preferred Stock | <u>(3)</u> | 02/07/2012 | | C | 750,000 <u>(3)</u> | <u>(3)</u> <u>(3)</u> | Common Stock 947,3 |
| Series B Convertible Preferred Stock | <u>(4)</u> | 02/07/2012 | | C | 768,637 <u>(4)</u> | <u>(4)</u> <u>(4)</u> | Common Stock 768,6 |
| Series B Convertible Preferred | <u>(4)</u> | 02/07/2012 | | C | 329,416 <u>(4)</u> | <u>(4)</u> <u>(4)</u> | Common Stock 329,4 |

Stock

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| INVESTOR AB C/O INVESTOR GROWTH CAPITAL ONE ROCKEFELLER PLAZA, SUITE 2801 NEW YORK, NY 10020 | | X | | |

Signatures

/s/ Michael

Oporto

02/09/2012

**Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Investor AB, a publicly held Swedish company (the "Reporting Person"), through one or more entities, (i) wholly owns Investor Growth Capital Limited ("Investor Capital"), a Guernsey company, and (ii) is the ultimate general partner of Investor Group, L.P. ("Investor Group"), a Guernsey limited partnership. As a result of the foregoing, the Reporting Person possesses the sole power to vote and the sole power to direct the disposition of the shares of Greenway Medical Technologies, Inc. (the "Company") held by each of Investor Capital and Investor Group.

(2) The Reporting Person's interest in all of the Company's securities is limited to the extent of its pecuniary interest in such securities, if any, and neither the filing of this statement nor any of its contents shall be deemed to constitute an admission by the Reporting Person or any other person/entity that he or it was or is the beneficial owner of any of the Company's securities for purposes of Section 16 of the Securities and Exchange Act of 1934 (the "Act"), or for any other purpose.

(3) Each share of Series A Convertible Preferred Stock automatically converted into 1.263 shares of common stock in connection with the completion of the Company's initial public offering and had no expiration date. In connection with the conversion, Investor Group also received 225,000 shares, and Investor Capital also received 525,000 shares, as additional payments in accordance with the terms of the Series A Convertible Preferred Stock.

(4) Each share of Series B Convertible Preferred Stock automatically converted into one share of common stock in connection with the completion of the Company's initial public offering and had no expiration date. In connection with the conversion, Investor Group also received 78,236 shares, and Investor Capital also received 182,551 shares, as additional payments in accordance with the terms of the Series B Convertible Preferred Stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.